136 related articles for article (PubMed ID: 27896475)
1. An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.
Ravegnini G; Nannini M; Zenesini C; Simeon V; Sammarini G; Urbini M; Gatto L; Saponara M; Biasco G; Pantaleo MA; Venturoli N; Hrelia P; Angelini S
Angiogenesis; 2017 Feb; 20(1):139-148. PubMed ID: 27896475
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
[TBL] [Abstract][Full Text] [Related]
4. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
6. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
[TBL] [Abstract][Full Text] [Related]
7. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
Vincenzi B; Nannini M; Fumagalli E; Bronte G; Frezza AM; De Lisi D; Spalato Ceruso M; Santini D; Badalamenti G; Pantaleo MA; Russo A; Dei Tos AP; Casali P; Tonini G
Oncotarget; 2016 Oct; 7(43):69412-69419. PubMed ID: 26416414
[TBL] [Abstract][Full Text] [Related]
8. Variants in angiogenesis-related genes and the risk of clear cell renal cell carcinoma.
Qin C; Chen J; Li J; Ju X; Zhang S; Cao Q; Han Z; Li P; Shao P; Wang M; Zhang Z; Gu M; Zhang W; Yin C
Mutagenesis; 2014 Nov; 29(6):419-25. PubMed ID: 25239121
[TBL] [Abstract][Full Text] [Related]
9. Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.
Maeng CH; Yi JH; Lee J; Hong JY; Choi MK; Jung HA; Park JO; Park SH; Park YS; Kang WK; Lim HY
Anticancer Res; 2013 Oct; 33(10):4619-26. PubMed ID: 24123039
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
[TBL] [Abstract][Full Text] [Related]
11. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
[TBL] [Abstract][Full Text] [Related]
12. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
van Erp NP; Eechoute K; van der Veldt AA; Haanen JB; Reyners AK; Mathijssen RH; Boven E; van der Straaten T; Baak-Pablo RF; Wessels JA; Guchelaar HJ; Gelderblom H
J Clin Oncol; 2009 Sep; 27(26):4406-12. PubMed ID: 19667267
[TBL] [Abstract][Full Text] [Related]
14. Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Eng L; Azad AK; Qiu X; Kong QQ; Cheng D; Ying N; Tse A; Kuang Q; Dodbiba L; Renouf DJ; Marsh S; Savas S; Mackay HJ; Knox JJ; Darling GE; Wong RK; Xu W; Liu G; Faluyi OO
Carcinogenesis; 2015 Sep; 36(9):956-62. PubMed ID: 26014353
[TBL] [Abstract][Full Text] [Related]
15. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Kim JJ; Vaziri SA; Rini BI; Elson P; Garcia JA; Wirka R; Dreicer R; Ganapathi MK; Ganapathi R
Cancer; 2012 Apr; 118(7):1946-54. PubMed ID: 21882181
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
Eechoute K; van der Veldt AA; Oosting S; Kappers MH; Wessels JA; Gelderblom H; Guchelaar HJ; Reyners AK; van Herpen CM; Haanen JB; Mathijssen RH; Boven E
Clin Pharmacol Ther; 2012 Oct; 92(4):503-10. PubMed ID: 22948895
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors.
Kang BW; Kim JG; Chae YS; Bae HI; Kwon O; Chung HY; Yu W; Song HS; Kang YN; Ryu SW; Lee KH; Bae YK; Choi JH; Kim SW; Ryoo HM; Cho CH; Chae HD; Park KW; Gu MJ; Bae BJ
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e40-5. PubMed ID: 23551429
[TBL] [Abstract][Full Text] [Related]
18. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
Demetri GD; Garrett CR; Schöffski P; Shah MH; Verweij J; Leyvraz S; Hurwitz HI; Pousa AL; Le Cesne A; Goldstein D; Paz-Ares L; Blay JY; McArthur GA; Xu QC; Huang X; Harmon CS; Tassell V; Cohen DP; Casali PG
Clin Cancer Res; 2012 Jun; 18(11):3170-9. PubMed ID: 22661587
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
20. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
